Vivani Medical Announces $8.25M Private Placement Equity Financing
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company’s once or twice-yearly GLP-1 (semaglutide) implant ...
TMCnet1d
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing
Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...
CNBCTV181d
Exclusive | Eli Lilly's Global CEO David Ricks says might make Mounjaro in India
GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...
IFLScience3dOpinion
Some Science Is Easy To Mock, But It Might Have Saved Your Life
Just because a research project sounds like a waste of money to people who know nothing of the topic, doesn’t mean it won’t ...